| Literature DB >> 36035174 |
Donald M Lamkin1,2,3, Shiuan Chen4, Karen P Bradshaw1,5, Shili Xu3,6,7, Kym F Faull2,8, Erica K Sloan1,3,9,10, Steve W Cole1,2,3,11.
Abstract
The low-dose mixture hypothesis of carcinogenesis proposes that exposure to an environmental chemical that is not individually oncogenic may nonetheless be capable of enabling carcinogenesis when it acts in concert with other factors. A class of ubiquitous environmental chemicals that are hypothesized to potentially function in this low-dose capacity are synthesized polybrominated diphenyl ethers (PBDEs). PBDEs can affect correlates of carcinogenesis that include genomic instability and inflammation. However, the effect of low-dose PBDE exposure on such correlates in mammary tissue has not been examined. In the present study, low-dose long-term (16 weeks) administration of PBDE to mice modulated transcriptomic indicators of genomic integrity and innate immunity in normal mammary tissue. PBDE increased transcriptome signatures for the Nuclear Factor Erythroid 2 Like 2 (NFE2L2) response to oxidative stress and decreased signatures for non-homologous end joining DNA repair (NHEJ). PBDE also decreased transcriptome signatures for the cyclic GMP-AMP Synthase - Stimulator of Interferon Genes (cGAS-STING) response, decreased indication of Interferon Stimulated Gene Factor 3 (ISGF3) and Nuclear Factor Kappa B (NF-κB) transcription factor activity, and increased digital cytometry estimates of immature dendritic cells (DCs) in mammary tissue. Replication of the PBDE exposure protocol in mice susceptible to mammary carcinogenesis resulted in greater tumor development. The results support the notion that ongoing exposure to low levels of PBDE can disrupt facets of genomic integrity and innate immunity in mammary tissue. Such effects affirm that synthesized PBDEs are a class of environmental chemicals that reasonably fit the low-dose mixture hypothesis.Entities:
Keywords: BDE-47; C3(1)/TAg; NF-κB; NFE2L2; NHEJ; breast cancer; cGAS-STING; type I interferon
Year: 2022 PMID: 36035174 PMCID: PMC9413140 DOI: 10.3389/fgene.2022.904607
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.772
FIGURE 1Effect of BDE-47 administration on mammary tissue levels. Mean ± SEM and individual data points for mice receiving 0.03 mg/kg/d of BDE-47 via subcutaneous osmotic mini-pump (n = 7) or vehicle only (n = 8) for 16 weeks **p < 0.01.
FIGURE 2Effect of BDE-47 administration on (A) xenobiotic AhR and (B) antioxidant NFE2L2 transcriptomes in mammary tissue. Left side: Mean ± SEM with overlay of individual TRA composite score data points, scores on log2 scale centered at zero, n = 7-8 mice per group. Right side: Heatmap of mean fold-changes on log2 scale for specific positively expressed genes from the reference transcriptome indicated in the panel. See text for references for gene sets. Complete lists for defining genes for each transcriptome are listed in Supplementary Data S1, S2. *p < 0.05.
FIGURE 4Effect of BDE-47 administration on (A) cGAS-STING transcriptome in mammary tissue. Left side: Mean ± SEM with overlay of individual TRA composite score data points, scores on log2 scale centered at zero, n = 7-8 mice per group. Right side: Heatmap of mean fold-changes on log2 scale for specific positively expressed genes from the reference transcriptome indicated in the panel. See text for references for gene sets. Defining genes for transcriptome are listed in Supplementary Data S4. (B) Effect of BDE-47 administration protocol on proinflammatory signaling pathways in mammary tissue as determined by TELiS analysis of transcription factor bining motifs (TFBM) in promoters of differentially expressed genes listed in Supplementary Data S5. *p < 0.05, ***p < 0.001.
FIGURE 5Effect of BDE-47 administration on (A) immature DCs and (B) activated DCs in mammary tissue as estimated by CIBERSORTx. Mean ± SEM. n = 7-8 mice per group. See text for reference for ImmuCC gene set. Defining genes for each cell population are listed in Supplementary Data S6. # p < 0.10.
FIGURE 6Effect of short-term PBDE administration on proinflammatory signaling pathways in mammary tissue as determined by TELiS analysis of transcription factor binding motifs (TFBM) in promoters of differentially expressed genes listed in Supplementary Data S7. # p < 0.10, ***p < 0.001.
FIGURE 7Effect of BDE-47 administration on mammary tumor development in the C3(1)/TAg model. Mean ± SEM and individual data points for (A) total volume of tumors and (B) total weight of tumors. Representative 10 mm 2D coronal slices, in maximum intensity projection (mip), from 3D PET/CT images of mice randomized to (C) only vehicle (n = 16) and (D) 0.03 mg/kg/d of BDE-47 (n = 19). White arrows indicate mammary tumors. Color scale is % ID/g, with threshold set to 3%; note that heart and bladder (and kidneys in the more dorsal 2D slice of panel D) serve as positive control tissue for [18F]-FDG in this scan protocol, with % ID/g > 13. **p < 0.01.
FIGURE 3TRA for DNA damage response pathways in mammary tissue after BDE-47 administration for (A) base excision repair (BER), (B) nucleotide excision repair (NER), (C) mismatch repair (MMR), (D) Fanconi anemia (FA), (E) translesion DNA synthesis (TLS), (F) direct damage reversal/repair (DR), (G) homology dependent recombination (HR), and (H) non-homologous end joining (NHEJ). Mean ± SEM with overlay of individual TRA composite score data points, scores on log2 scale centered at zero, n = 7-8 mice per group. See text for reference for gene sets. Complete lists for defining genes for each transcriptome are listed in Supplementary Data S3. *p < 0.05.